|
AU2011207563B2
(en)
|
2010-01-19 |
2016-03-10 |
Northwestern University |
Synthetic nanostructures including nucleic acids and/or other entities
|
|
US20130101512A1
(en)
*
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
|
WO2011130749A2
(en)
|
2010-04-16 |
2011-10-20 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012159164A1
(en)
*
|
2011-05-23 |
2012-11-29 |
Phylogica Limited |
Method of determining, identifying or isolating cell-penetrating peptides
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
AU2012358181A1
(en)
*
|
2011-12-23 |
2014-07-10 |
Egen, Inc. |
Compositions and methods for the delivery of biologically active RNAs
|
|
WO2013101690A1
(en)
*
|
2011-12-29 |
2013-07-04 |
modeRNA Therapeutics |
Modified mrnas encoding cell-penetrating polypeptides
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
US9909123B2
(en)
*
|
2013-03-15 |
2018-03-06 |
Techulon Inc. |
Antisense molecules for treatment of Staphylococcus aureus infection
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2015002956A1
(en)
*
|
2013-07-01 |
2015-01-08 |
Ohio State Innovation Foundation |
Exosome delivery system
|
|
EP3024936B1
(en)
|
2013-07-25 |
2019-09-04 |
Exicure, Inc. |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
|
US10568898B2
(en)
|
2013-08-13 |
2020-02-25 |
Northwestern University |
Lipophilic nanoparticles for drug delivery
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
BR112016009465A8
(pt)
|
2013-10-28 |
2018-01-30 |
Univ Pittsburgh Commonwealth Sys Higher Education |
vetor de hsv oncolítico.
|
|
JP6744224B2
(ja)
|
2014-02-14 |
2020-08-19 |
シンヴィヴォ コーポレイション |
核酸ベクターおよびその使用
|
|
TR201908550T4
(tr)
|
2014-06-04 |
2019-07-22 |
Exicure Inc |
Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
|
|
WO2016028940A1
(en)
|
2014-08-19 |
2016-02-25 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
|
CR20170181A
(es)
|
2014-10-06 |
2017-05-31 |
Exicure Inc |
Compuestos anti-tnf
|
|
US9816080B2
(en)
*
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
|
US10078092B2
(en)
|
2015-03-18 |
2018-09-18 |
Northwestern University |
Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
|
|
KR20180136435A
(ko)
|
2016-01-27 |
2018-12-24 |
온코루스, 인크. |
종양 살상형 바이러스 벡터 및 그의 용도
|
|
US11639371B2
(en)
*
|
2016-02-17 |
2023-05-02 |
The Chinese University Of Hong Kong |
Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
|
|
CN109414414A
(zh)
|
2016-03-16 |
2019-03-01 |
戴维·格拉德斯通研究所 |
用于治疗肥胖症和/或糖尿病以及用于鉴定候选治疗剂的方法和组合物
|
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
US11612625B2
(en)
|
2017-07-26 |
2023-03-28 |
Oncorus, Inc. |
Oncolytic viral vectors and uses thereof
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
EP3818167A4
(en)
*
|
2018-07-05 |
2022-04-13 |
The Regents of The University of California |
COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL
|
|
WO2021062196A1
(en)
|
2019-09-26 |
2021-04-01 |
President And Fellows Of Harvard College |
Minimal arrestin domain containing protein 1 (arrdc1) constructs
|
|
US20250263690A1
(en)
*
|
2022-06-15 |
2025-08-21 |
Duke University |
Protein library display systems and methods thereof
|